Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve This is to inform you that the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd has informed BSE that its Board of Directors will meet on Friday, 13th February 2026 at 5 PM at its corporate office in Chennai. The main agenda is to consider and approve the unaudited financial results for the quarter ended 31st December 2025 (Q3 FY26), in line with SEBI listing regulations. The meeting also has a standard agenda item allowing the board to discuss any other matter with the Chairman's permission. The trading window for promoters, directors, designated employees, and connected persons has been closed until 48 hours after the results are announced. No financial figures or performance details are disclosed in this intimation; the actual results will be shared after the board meeting.
This is a routine regulatory filing with no immediate impact on shareholders. Investors should watch for the Q3 FY26 results announcement on or after 13th February 2026 for any material updates on revenue, profitability, or business outlook that could influence the stock price.